# Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

> **NCT06876532** · NA · RECRUITING · sponsor: **Institut Claudius Regaud** · enrollment: 150 (estimated)

## Conditions studied

- Intestinal Neuroendocrine Tumor

## Interventions

- **OTHER:** Additional blood tests (CRP and serum albumin) and data collection.

## Key facts

- **NCT ID:** NCT06876532
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2029-04
- **Final completion:** 2031-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06876532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06876532, "Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06876532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*